The FDA extended its review of Merus' cancer treatment zenocutuzumab, setting a new target action date for Feb. 4. The company submitted information related to manufacturing and controls, with no request for additional clinical data.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing